Is retatrutide legal in Australia?
Retatrutide is an investigational compound that is not approved by the TGA and not listed on the ARTG. This page explains its regulatory status and what research use only means. General information only, not legal or medical advice.
The short answer
Retatrutide is not an approved medicine in Australia. As at 2026 it has not been evaluated or approved by the Therapeutic Goods Administration (TGA) for any therapeutic use, and it is not listed on the Australian Register of Therapeutic Goods (ARTG). It remains an investigational compound in global clinical trials.
Because it is not an approved therapeutic good, retatrutide is supplied here strictly as a research compound for laboratory and research use only. It is not supplied for human or animal use, and nothing on this page should be read as encouragement or instruction to use it in any person.
General information only. This is not legal advice or medical advice. Regulatory status can change. Always confirm the current position with the TGA and a qualified professional before acting.
What retatrutide is
Retatrutide, also referenced by its development code LY3437943, is an investigational peptide being developed by Eli Lilly. It is described in the published literature as a single molecule that acts on three receptor pathways at once, the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. For this reason it is often called a triple agonist or a GGG agonist.
It sits in the same broad pharmacological family as other GLP-1 based compounds that are the subject of ongoing clinical investigation. That family context matters in Australia because of how the TGA treats this class, which is covered further down this page.
What stage of development it is at
Retatrutide is reported to be in Phase 3 clinical development, the stage at which a candidate is tested in larger trials before any regulator decides whether to approve it. Eli Lilly runs this work under a programme publicly described as TRIUMPH, which spans several separate trials.
Being in Phase 3 means a compound is still experimental. It has not completed the regulatory review that an approved medicine has passed. A candidate can be in late-stage trials and still never reach approval, or reach approval in one country before others.
TGA and ARTG status in Australia
The ARTG is the public register of therapeutic goods that have been assessed and approved for supply in Australia. If a medicine is approved for the Australian market, it appears on the ARTG with an AUST R or AUST L number. As at 2026, retatrutide does not appear on the ARTG and has not been approved by the TGA for any indication.
Public reporting indicates that Eli Lilly has signalled an intention to seek approval from the United States Food and Drug Administration, with industry coverage pointing to a submission window around late 2026 to early 2027. Any Australian approval would be a separate process handled by the TGA on its own timeline, and no such approval exists today. We make no prediction about if or when that might happen.
An unapproved compound cannot be lawfully supplied, advertised or sold in Australia as a medicine for human use. Supply as a research chemical for laboratory use is a different and narrower category, and that is the only basis on which retatrutide is offered here.
Scheduling and advertising context
Medicines in Australia are classified under the Poisons Standard, also called the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). Prescription-only medicines generally sit in Schedule 4. Retatrutide itself does not have a settled approved-product scheduling entry because it is not an approved medicine, so its day-to-day status is best understood as unapproved and experimental rather than as a registered Schedule 4 product.
Separately, the TGA restricts the advertising of prescription medicines to the public, and it has issued guidance addressing the promotion of GLP-1 based compounds to consumers. The practical effect is that this class is not something that can be marketed to the public as a weight or metabolic product. For that reason this page makes no therapeutic or efficacy claims of any kind.
Key regulatory reference points
- Therapeutic Goods Act 1989 and the ARTG, which govern approval and supply
- The Poisons Standard (SUSMP), which governs scheduling
- TGA advertising rules, which restrict promotion of prescription and GLP-1 class compounds to the public
What research use only actually means
Research use only means a compound is supplied to be used in a controlled laboratory setting by people equipped to handle research chemicals, not to be administered to humans or animals. It is a materially different category from an approved medicine.
How a research compound differs from an approved medicine
- An approved medicine has passed TGA assessment and carries an ARTG number. A research compound has not.
- An approved medicine comes with a prescribing framework and a Product Information document. A research compound does not.
- An approved medicine is supplied for a defined therapeutic use. A research compound is supplied for laboratory investigation only.
- An approved medicine may be advertised within strict rules. A research compound must not be promoted for human use at all.
NovaPeptides supplies retatrutide for laboratory research use only. We do not supply it for human or animal use, we provide no dosing information, and we make no therapeutic claims. Buyers are responsible for using research materials lawfully and safely.
Anti-doping and sport
Athletes and support staff bound by anti-doping rules should not assume that an unapproved or experimental compound is permitted in sport. The World Anti-Doping Agency (WADA) Prohibited List includes a category for substances that have not been approved by a government regulatory authority for human therapeutic use, which can capture investigational compounds.
Anyone subject to anti-doping rules should check the current WADA Prohibited List and seek guidance from Sport Integrity Australia before assuming anything about a given substance. We do not make or confirm any claim about a specific status, because that status is set by WADA and can change.
Sourcing and verification notes
Because research compounds are not regulated like approved medicines, documentation and traceability matter. Where retatrutide is offered as a research compound, we pair it with batch level documentation so the material can be independently verified rather than taken on trust.
What to look for in any research supplier
- A Certificate of Analysis (CoA) tied to the specific batch, not a generic document
- Independent laboratory analysis rather than self-reported figures only
- Clear research use only labelling and no therapeutic claims
- Transparent batch identifiers so a result can be matched to the vial
Every NovaPeptides batch carries a Novagen Certificate of Analysis so the identity and purity of the research material can be checked against the batch it belongs to.
Frequently asked questions
Is retatrutide legal to buy in Australia?+
Retatrutide is not an approved medicine in Australia and is not on the ARTG. It cannot be lawfully supplied for human use. It is offered here only as a research compound for laboratory use. This is general information, not legal advice, so confirm the current position with the TGA and a qualified professional.
Is retatrutide approved by the TGA?+
No. As at 2026 the TGA has not approved retatrutide for any therapeutic indication, and it does not appear on the Australian Register of Therapeutic Goods.
Is retatrutide on the ARTG?+
No. It is not listed on the ARTG. An unlisted compound has not been assessed or approved for supply as a medicine in Australia.
What stage is retatrutide at in development?+
It is reported to be in Phase 3 clinical trials under Eli Lilly's TRIUMPH programme. Phase 3 is a late trial stage that precedes any regulatory decision, so the compound remains investigational.
Can a doctor prescribe retatrutide in Australia?+
Retatrutide is not an approved, registered medicine in Australia, so it is not a standard prescription product. Questions about access pathways should be directed to a qualified medical professional and the TGA, not to a research supplier.
Is retatrutide banned in sport?+
Anyone bound by anti-doping rules should not assume an investigational compound is permitted. Unapproved substances can fall under a WADA Prohibited List category. Check the current WADA list and Sport Integrity Australia before assuming any status.
What does research use only mean for retatrutide?+
It means the compound is supplied for laboratory research only, not for human or animal use. It carries no dosing guidance and no therapeutic claims, and it is a different category from an approved medicine.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp